

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

PRO PHARMACEUTICALS INC  
Form 8-K  
February 25, 2002

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 15, 2002

PRO-PHARMACEUTICALS, INC.  
(Exact Name of Registrant as Specified in its Charter)

Nevada  
(State or Other Jurisdiction of Incorporation)

000-32877  
(Commission File Number)

04-3562325  
(IRS Employer Identification No.)

189 Wells Avenue, Suite 200, Newton, Massachusetts  
(Address of Principal Executive Offices)

02459  
(Zip Code)

(617) 559-0033  
(Registrant's Telephone Number, Including Area Code)

Not Applicable  
(Former Name or Former Address, If Changed Since Last Report)

Item 4. Changes in Registrant's Certifying Accountant

On February 15, 2002, the management of Pro-Pharmaceuticals, Inc. (the "Registrant"), dismissed Scillia Dowling & Natarelli LLC as its independent auditors. On February 22, 2002, the management of the Registrant engaged Deloitte & Touche LLP as its independent auditors to audit its financial statements for the fiscal year ended December 31, 2001. The decision to dismiss Scillia Dowling & Natarelli LLC and to retain Deloitte & Touche LLP was approved by the Registrant's Board of Directors and Audit Committee.

The report of Scillia Dowling & Natarelli LLC on the Registrant's financial statements as of December 31, 2000, and the review reports of Scillia Dowling & Natarelli LLC on the Registrant's financial statements as of June 30, 2001 and September 30, 2001 and for the three-month and year-to-date periods, did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles. From March 31, 2001 through February 15, 2002, there were no disagreements between Scillia Dowling & Natarelli LLC and the Registrant on any matter of accounting

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Scillia Dowling & Natarelli LLC, would have caused it to make reference to the subject matter of the disagreement in connection with its reports on the Registrant's financial statements.

From March 31, 2001, the Registrant did not consult with Deloitte & Touche LLP on items which involved (i) the application of accounting principles to a specified transaction, either completed or proposed, (ii) the type of audit opinion that might be rendered on the Registrant's financial statements, or (iii) the subject matter of a disagreement or "reportable event."

The Registrant has furnished Scillia Dowling & Natarelli LLC with a copy of this report and has requested it to furnish a letter addressed to the Securities and Exchange Commission stating whether Scillia Dowling & Natarelli LLC agrees with the above statements. A copy of this letter is attached as Exhibit 16 to this Form 8-K.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

(c) Exhibits

Exhibit Number -----	Description of Document -----
16	Letter from Scillia Dowling & Natarelli LLC to the Commission, dated February 25, 2002, concerning change in certifying accountant

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PRO-PHARMACEUTICALS, INC.  
(Registrant)

By: /s/ David Platt  
-----  
David Platt, President

Date: February 25, 2002

EXHIBIT INDEX

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

Exhibit  
Number  
-----

Description of Document  
-----

16

Letter from Scillia Dowling & Natarelli LLC to the  
Commission, dated February 25, 2002, concerning change in  
certifying accountant